Litcius/Paper detail

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies

Jared Weiss, Jerome H. Goldschmidt, Zoran Andrić, Konstantin H. Dragnev, Chad Gwaltney, Konstantina Skaltsa, Yili Pritchett, Joyce Antal, Shannon R. Morris, Davey B. Daniel

2021Clinical Lung Cancer68 citationsDOI

Topics & Concepts

MedicineInternal medicineChemotherapyCarboplatinNeutropeniaPlaceboOncologyLung cancerEtoposideFebrile neutropeniaChemotherapy regimenTopotecanSurgeryPathologyCisplatinAlternative medicineAdvanced Breast Cancer TherapiesLung Cancer Research StudiesMultiple Myeloma Research and Treatments
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies | Litcius